登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688247 证券简称：宣泰医药 公告编号：2025-031 上海宣泰医药科技股份有限公司 关于控股股东自愿承诺不减持公司股份的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 上海宣泰医药科技股份有限公司（以下简称"公司"）于2025年8月15日收到公司控股股东上海联和投资 有限公司（以下简称"联和投资"）出具的《关于自愿承诺未来24个月不减持上海宣泰医药科技股份有限 公司股份的承诺函》。现将相关情况公告如下： 基于对公司未来发展前景的信心和对公司长期价值的认可，同时为增强广大投资者信心，切实维护投资 者权益和资本市场稳定，公司控股股东联和投资自愿承诺，自2025年8月25日起24个月内（2025年8月25 日至2027年8月24日）不通过集中竞价交易、大宗交易等方式减持其所持有的公司股份。在上述承诺期 间，如发生资本公积转增股本、派送股票红利、配股等产生新增股份，亦遵守该不减持承诺。 截至本公告披露日，公司控股股东联和投资持股情况如下： ■ 公司董事会将对 ...

Mergers and Acquisitions - Huahong Company is planning to acquire controlling stakes in Shanghai Huali Microelectronics through a combination of issuing shares and cash payments to resolve competition issues related to its IPO [1] Performance Disclosure - Guangku Technology reported a revenue of 597 million yuan for the first half of 2025, representing a year-on-year increase of 41.58%, with a net profit attributable to shareholders of 51.87 million yuan, up 70.96% [2] - Huayou Cobalt disclosed a revenue of 37.2 billion yuan for the first half of 2025, showing a year-on-year growth of 23.78%, with a net profit of 2.711 billion yuan, an increase of 62.26% [3] - Guangli Micro reported a revenue of 246 million yuan for the first half of 2025, reflecting a year-on-year increase of 43.17%, with a net profit of 15.6842 million yuan, up 518.42% [4] Shareholding Changes - Nanwei Medical announced that its shareholder Zhongke Investment plans to reduce its stake by up to 2%, equating to a maximum of 3.7569 million shares [5] - Shandong Zhanggu reported that shareholders Niu Yusheng and Fang Shupeng completed their plan to reduce their holdings by approximately 700,000 shares, representing 0.225% of the total share capital [6] - Xuantai Pharmaceutical's controlling shareholder voluntarily committed not to reduce its stake for 24 months starting from August 25, 2025, to enhance investor confidence [7] Risk Matters - Guotai Environmental announced that its controlling shareholder and chairman Chen Baixiao has been placed under detention and is under investigation [8] - *ST Xinchao reported that a lawsuit has been adjudicated, and the company expressed regret for not disclosing relevant information during a management transition [9] - Shandong Zhanggu stated that there have been no significant changes in its operational situation or external environment despite a recent stock price fluctuation exceeding 20% [10]

Core Viewpoint - The controlling shareholder of Shanghai Xuantai Pharmaceutical Technology Co., Ltd. has voluntarily committed not to reduce its shareholding in the company for the next 24 months, aiming to enhance investor confidence and maintain market stability [1][2]. Shareholder Commitment - The controlling shareholder, Shanghai Lianhe Investment Co., Ltd., has issued a commitment letter stating that from August 25, 2025, to August 24, 2027, it will not reduce its shareholding through various trading methods [1]. - This commitment includes adherence to the non-reduction promise in the event of capital reserve conversion into share capital, stock dividends, or rights issues that generate new shares [1]. Shareholding Status - As of the announcement date, the shareholding status of the controlling shareholder is detailed, although specific numbers and percentages are not provided in the text [1].

证券代码：688247 证券简称：宣泰医药 公告编号：2025-032 上海宣泰医药科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 本次股票上市类型为首发限售股份；股票认购方式为网下，上市股数为 本次股票上市流通总数为311,018,400股。 ? 本次股票上市流通日期为2025 年 8 月 25 日。 一、本次上市流通的限售股类型 根据中国证券监督管理委员会《关于同意上海宣泰医药科技股份有限公司首 次公开发行股票注册的批复》 三、本次上市流通的限售股的有关承诺 根据《上海宣泰医药科技股份有限公司首次公开发行股票并在科创板上市招 股说明书》及《上海宣泰医药科技股份有限公司关于控股股东自愿承诺不减持公 司股份的公告》，本次申请解除股份限售的股东关于其持有的限售股的有关承诺如 下： （一） 关于限售安排、自愿锁定及延长锁定期限承诺 （证监许可[2022]1383 号），上海宣泰医药科技股份有 限公司（以下简称"公司"、 "宣泰医药"）获准向社会公开发行人民币普通股（A） 股 45,340, ...

Group 1 - The controlling shareholder, Shanghai Lianhe Investment Co., Ltd., has committed not to reduce its shareholding in Xuantai Pharmaceutical for 24 months starting from August 25, 2025, to enhance investor confidence and stabilize the capital market [1] - On August 25, 2023, a total of 311 million shares of Xuantai Pharmaceutical will be unlocked, accounting for 68.61% of the total share capital, with Lianhe Investment holding 233 million shares, representing 75% of the unlocked shares [1] - The commitment from the controlling shareholder significantly reduces the potential share reduction to 7.8 million shares, alleviating market liquidity pressure [1] Group 2 - Xuantai Pharmaceutical focuses on high-end generic drugs and has developed a leading drug chemical formulation platform in China, with a strong emphasis on R&D and technological innovation [2] - The company has established differentiated technological barriers in areas such as "insoluble drug solubilization technology" and "controlled-release technology," facilitating the transition from price competition to high value-added development [2] - As of the end of 2024, Xuantai Pharmaceutical is expected to have 16 approved products, including several first-generic products domestically and internationally, with products already exported to multiple countries [2] Group 3 - Since its listing in 2022, Xuantai Pharmaceutical has maintained a shareholder-centric approach, optimizing management and governance, and has distributed a total cash dividend of 74.36 million yuan over three years [3] - The company completed a share buyback in February 2025, repurchasing 4.3361 million shares, which is 0.96% of the total share capital, at a cost of 36.126 million yuan [3] - Xuantai Pharmaceutical plans to continue its dual-driven strategy of innovation and international expansion to accelerate product commercialization and deliver stable returns to investors [3]

Core Viewpoint - The controlling shareholder of Xuantai Pharmaceutical, Shanghai Lianhe Investment Co., Ltd., has voluntarily committed not to reduce its shareholding in the company for 24 months starting from August 25, 2025, to enhance investor confidence and maintain market stability [1][2]. Group 1: Shareholder Commitment - The commitment from the controlling shareholder comes at a critical time when the company's original shareholders' restricted shares are about to be unlocked, alleviating market concerns about large-scale share reductions [2]. - On August 25, 2023, a total of 311 million shares will be unlocked, accounting for 68.61% of the total share capital, with Lianhe Investment holding 233 million shares, representing 75% of the unlocked shares [2]. - The actual reducible shares will be significantly reduced to 7.8 million shares, effectively easing potential liquidity pressure from the concentrated unlocking [2]. Group 2: Business Strengths - Xuantai Pharmaceutical's long-term outlook is supported by its robust core strategic business and the competitive barriers of its high-end formulation technology [3]. - The company focuses on high-end generic drugs and has developed a leading drug chemical formulation platform in China, with a strong emphasis on R&D and technological innovation [3]. - The product portfolio includes 16 approved products by the end of 2024, with several being first generics in both domestic and international markets [3]. Group 3: CRO/CMO Performance - In the CRO/CMO sector, Xuantai Pharmaceutical has successfully assisted in the approval and commercialization of multiple innovative drugs, with over 100 projects completed for global clients [4]. - The company has established partnerships with several well-known pharmaceutical companies, enhancing its market presence and service capabilities [4]. Group 4: Shareholder Returns - Xuantai Pharmaceutical has consistently prioritized shareholder returns, implementing a stable and continuous dividend policy, with a total cash dividend of 74.36 million yuan since its listing in 2022 [5][6]. - The company completed a share buyback in February 2025, repurchasing 4.3361 million shares, which represents 0.96% of the total share capital, further demonstrating its commitment to enhancing shareholder value [6]. - The controlling shareholder's commitment not to reduce holdings is seen as a strong vote of confidence in the company's long-term strategy and management team, reinforcing the company's positive image in the capital market [6].

公告显示，基于对公司未来发展前景的信心和对公司长期价值的认可，同时为增强广大投资者信心，切 实维护投资者权益和资本市场稳定，公司控股股东联和投资自愿承诺，自8月25日起24个月内不通过集 中竞价交易、大宗交易等方式减持其所持有的公司股份。 北京商报讯(记者丁宁)8月17日晚间，宣泰医药(688247)发布公告称，公司于8月15日收到公司控股股东 上海联和投资有限公司(以下简称"联和投资")出具的《关于自愿承诺未来24个月不减持上海宣泰医药科 技股份有限公司股份的承诺函》。 ...

2024年1至12月份，宣泰医药的营业收入构成为：医药制造业占比99.89%，其他业务占比0.11%。 （文章来源：每日经济新闻） 宣泰医药（SH 688247，收盘价：12.35元）8月17日晚间发布公告称，公司限售股份约3.11亿股将于2025 年8月25日解禁并上市流通，占公司总股本比例为68.61%。 ...

证券代码：688247 证券简称：宣泰医药 公告编号：2025-032 上海宣泰医药科技股份有限公司 首次公开发行部分限售股上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为首发限售股份；股票认购方式为网下，上市股数为 311,018,400股。 本次股票上市流通总数为311,018,400股。 本次股票上市流通日期为2025 年 8 月 25 日。 一、本次上市流通的限售股类型 根据中国证券监督管理委员会《关于同意上海宣泰医药科技股份有限公司首 次公开发行股票注册的批复》（证监许可[2022]1383 号），上海宣泰医药科技股份有 限公司（以下简称"公司"、"宣泰医药"）获准向社会公开发行人民币普通股（A） 股 45,340,000.00 股，并于 2022 年 8 月 25 日在上海证券交易所科创板上市，发行 完成后公司总股本为 453,340,000 股，其中有限售条件流通股为 412,430,080 股， 无限售条件流通股为 40,909,920 股。 本次上市流通的限 ...

国泰海通证券股份有限公司 国泰海通证券股份有限公司（以下简称"国泰海通"、"保荐机构"）作 为上海宣泰医药科技股份有限公司（以下简称"宣泰医药"或"公司"）首次 公开发行股票并在科创板上市的保荐机构，根据《证券发行上市保荐业务管理 办法》《上海证券交易所科创板股票上市规则》《上海证券交易所科创板上市 公司自律监管指引第 1 号——规范运作》等有关规定，对宣泰医药首次公开发 行部分限售股上市流通事项进行了审慎核查，具体情况如下： 一、本次上市流通的限售股类型 根据中国证券监督管理委员会《关于同意上海宣泰医药科技股份有限公司首 次公开发行股票注册的批复》（证监许可[2022]1383 号），公司获准向社会公开 发行人民币普通股（A）股 45,340,000.00 股，并于 2022 年 8 月 25 日在上海证 券交易所科创板上市，发行完成后公司总股本为 453,340,000 股，其中有限售条 件流通股为 412,430,080 股，无限售条件流通股为 40,909,920 股。 本次上市流通的限售股为公司首次公开发行的部分限售股，限售股股东数量 为 5 名，限售期为自公司股票上市之日起 36 个月，该部分限售 ...